Dasatinib, Nilotinib Have Similar Favorable Results Against CML

Patients with early chronic phase chronic myeloid leukemia (CML) have high response rates to either dasatinib (Sprycel) or nilotinib (Tasigna), according to two papers reported online December 14 in the Journal of Clinical Oncology. Reuters Health Information

More on Sciencestage.com

    More on Wikipedia

      Related Videos

        More on answers.yahoo.com

          More on Pubmed

            More on Answers.com